(tizanidine)
2 mg, 4 mg and 6 mg Tablets
6 mg and 12 mg MR Capsules

Presentation:
Tablets containing 2 mg, 4 mg or 6 mg tizanidine hydrochloride; MR (modified release) capsules containing 6 mg or 12 mg tizanidine hydrochloride.

Indications:
Painful muscle spasms associated with static and functional disorders of the spine (cervical and lumbar syndromes) or following surgery, e.g. for herniated intervertebral disc or osteoarthritis of the hip. Spasticity due to neurological disorders such as multiple sclerosis, chronic myelopathy, degenerative spinal cord diseases, cerebrovascular accidents, and cerebral palsy.

Dosage:
*Painful muscle spasms*: 2 to 4 mg three times daily in tablet form.

*Spasticity due to neurological disorders*: Tablets: maximum initial dose 6 mg/day in 3 divided doses, then increase stepwise to achieve optimum therapeutic response (generally between 12 to 24 mg/day). The daily dose of 36 mg should not be exceeded.

*MR capsules*: initial dose 6 mg once a day which may be increased stepwise from 6 to 24 mg/day as necessary.

Contraindications:
Known hypersensitivity to tizanidine or any component of the formulations.
Significantly impaired hepatic function.
Concomitant use with strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin.

Precautions/Warnings:
Co-administration with inhibitors of CYP1A2 such as some antiarrhythmics (amiodarone, mexiletine, propafenone), cimetidine, some fluoroquinolones (enoxacin, pefloxacin, norfloxacin), rofecoxib, oral contraceptives and ticlopidine is not recommended (see also Contraindications).
Hypotension may occur with potential severe symptoms such as loss of consciousness and circulatory collapse.
Gradual reduction in dosage is recommended to avoid withdrawal syndrome.
Liver function tests recommended in patients receiving doses of 12 mg or above and in case of clinical symptoms suggestive of hepatic dysfunction; discontinue treatment if serum levels of SGPT or SGOT are persistently above three times the upper limit of the normal range.
Caution in patients with impaired kidney function.
Refrain from driving a vehicle or using machines if dizziness or hypotension occurs.
Use during pregnancy only if benefit clearly outweighs the risk.
Avoid breastfeeding.
Use in children not recommended and caution in elderly patients.

For Siralud tablets only: not recommended in patients with rare hereditary problems of galactose intolerance, of severe lactase deficiency or of glucose-galactose malabsorption.

Interactions:
CYP1A2 inhibitors; antihypertensives including diuretics; alcohol; sedatives.

Adverse reactions:
With low doses, such as those recommended for the relief of painful muscle spasms: somnolence, fatigue, dizziness, dry mouth, nausea, gastrointestinal disorder, transaminase increase, blood pressure decrease.
With the higher doses, as recommended for the treatment of spasticity, in addition: muscular weakness, insomnia, sleep disorder, hallucination, hypotension, bradycardia, hepatitis and hepatic failure.

Withdrawal syndrome: rebound hypertension and...
tachycardia possibly leading to cerebrovascular accident.

**Packs and prices:** Country specific.

**Note:** Before prescribing, please read full prescribing information.